



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/199912/>

Version: Published Version

Article:

Gwathmey, K.G., Corcia, P., McDermott, C.J. et al. (2023) Diagnostic delay in amyotrophic lateral sclerosis. *European Journal of Neurology*, 30 (9). pp. 2595-2601. ISSN: 1351-5101

<https://doi.org/10.1111/ene.15874>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

POSITION PAPER

Diagnostic delay in amyotrophic lateral sclerosis

Kelly G. Gwathmey¹  | Philippe Corcia^{2,3}  | Chris J. McDermott⁴  | Angela Genge⁵  |
Stefan Sennfält^{6,7}  | Mamede de Carvalho^{8,9}  | Caroline Ingre^{6,7} 

¹Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA

²CRM SLA, CHU Tours, Tours, France

³UMR1253 iBrain UMR, Université de Tours, INSERM, Tours, France

⁴Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK

⁵Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

⁶Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

⁷Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

⁸Institute of Physiology, Instituto de Medicina Molecular João Lobo Antunes, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

⁹Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa-Norte, Lisbon, Portugal

Correspondence

Kelly G. Gwathmey, Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
Email: kelly.gwathmey@vcuhealth.org

Funding information

Cytokinetics

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease, and the time from symptom onset to diagnosis remains long. With the advent of disease-modifying treatments, the need to identify and diagnose ALS in a timely fashion has never been greater.

Methods: We reviewed the literature to define the severity of ALS diagnostic delay, the various factors that contribute to this delay (including patient and physician factors), and the role that site of symptom onset plays in a patient's diagnostic journey.

Results: Diagnostic delay is influenced by general practitioners' lack of recognition of ALS due to disease rarity and heterogenous presentations. As a result, patients are referred to non-neurologists, have unnecessary diagnostic testing, and may ultimately be misdiagnosed. Patient factors include their illness behavior—which impacts diagnostic delay—and their site of symptom onset. Limb-onset patients have the greatest diagnostic delay because they are frequently misdiagnosed with degenerative spine disease or peripheral neuropathy.

Conclusion: Prompt ALS diagnosis results in more effective clinical management, with earlier access to disease-modifying therapies, multidisciplinary care, and, if desired, clinical trial involvement. Due to lack of commercially available ALS biomarkers, alternative strategies to identify and triage patients who likely have ALS must be employed. Several diagnostic tools have been developed to encourage general practitioners to consider ALS and make an urgent referral to ALS specialists, bypassing unnecessary referrals to non-neurologists and unnecessary diagnostic workup.

KEY WORDS

amyotrophic lateral sclerosis, diagnostic errors, delayed diagnosis, motor neurone disease, neurodegenerative diseases

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is an illness in which the interval from the time an individual experiences a symptom to the point at which they are diagnosed remains long. Recent reports that

outcomes for people living with ALS (PlwALS) are improved when treatments are started earlier—on top of previously identified benefits, including timely initiation of multidisciplinary care and riluzole—merit the field exploring both the causes for diagnostic delay and what measures can be taken to minimize it.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Diagnostic delay is reported to range from 9.1 to 27 months [1]. Most PlwALS are diagnosed in King's Stage 2 (second region involved), when 40% of the total disease duration has elapsed [2]. The revised Amyotrophic Lateral Sclerosis Functional Rating Scale score at diagnosis in a large US clinic population with a mean diagnostic delay of 1 (standard deviation [SD] 0.6–1.7) year was 37 (SD $\pm$ 6) [3]. The same population had a forced vital capacity of 81%.

Several studies have reported that patients with bulbar onset are diagnosed more quickly than those with limb onset [4–10]. Although some studies indicated that young male patients are diagnosed more quickly than female and older patients, other studies demonstrated that the odds of delayed diagnosis (≥ 12 months) were higher in younger patients (≤ 45 years) and that female gender was independently associated with earlier diagnosis [6, 7, 9–11]. In addition, slow progression is strongly associated with a longer diagnostic delay, a well-known independent predictor of prognosis in ALS [12–14].

There is strong evidence that faster review by a neurologist shortens the diagnostic time: one study described that only 16% of PlwALS were first assessed by a neurologist, but in 56% of these, the diagnosis was made immediately, as compared with 1% when the patients were first seen by another medical doctor [10, 12, 13, 15]. Supporting this observation, in the United Kingdom, fast-track referral to a neurologist shortened the time from referral to diagnosis by 50% [16]. In a recent study in five European countries, including a total of 1405 patient journeys, the median diagnostic delay was 11 months and similar in the various centers. In this study, the major determinant for a faster diagnosis was time to observation by a neurologist [12].

We would anticipate a shorter diagnostic delay in PlwALS with a positive family history of ALS and in those living in urban areas. The former has been suggested in two previous reports but not confirmed in another study with a larger number of patients [6, 12, 13]. Taking into account that only 10% of patients have a positive family history, most studies are not powered to detect differences. In addition, living in rural areas does not increase the delay between symptom onset and diagnosis [12, 17].

The delay is multifactorial and, although this makes addressing the issue a challenge, this means there may be multiple points at which to influence the diagnostic process.

BEHAVIORAL FACTORS

The illness behavior of PlwALS contributes to diagnostic delay, with patients not seeking medical advice for the presenting symptom of ALS for up to 6 months [4–6, 18–20]. Illness behavior is influenced by socioeconomic factors, personality, psychological and psychiatric comorbidity, and age [21]. Indeed, it has been shown that lower income was associated with increased diagnostic delay in ALS, and cognitive changes have a negative impact on early diagnosis [12]. Having a private medical consultation was associated with a shorter diagnostic delay, reflecting the advantage of rapid access to neurologists for a shorter diagnostic time.

BEHAVIORAL FACTORS—PHYSICIANS

Primary care physicians are most often the first to see PlwALS when they do seek out medical advice [4, 10, 20]. Given the rarity of ALS, the challenge facing the primary care physician is the real chance that the first case they see may be the only case of ALS they see [22]. The decision to refer into secondary care was delayed by up to 5 months in one study in Northern Ireland [11]. An earlier referral does not need the primary care physician to necessarily make a diagnosis of ALS; it just requires recognition that something is neurological and does not fit a pattern they often see [22].

Patients with ALS are most likely to have a shorter diagnostic journey if they are referred to a neurologist [10, 12, 15]. Delays are reported when patients are first referred to other specialties, for example, ear, nose and throat, and orthopedics (Figure 1) [1, 4–6, 9, 10, 15–20, 23–27].

In a study of 73 patients with motor neurone disease (MND) in Belfast, Northern Ireland, 27% of patients were initially misdiagnosed, with incorrect diagnoses for these patients being cervical spondylosis, neuropathy, lumbar disc prolapse, shoulder capsulitis, myelopathy, stroke, carpal tunnel syndrome, vascular pseudobulbar palsy, osteoarthritis, rhinitis, depression, or being told nothing was wrong [11]. A study in 304 MND patients at Massachusetts General Hospital reported that 52% had been initially misdiagnosed [6]. The diversity of misdiagnosis has been well summarized elsewhere [1].

DIAGNOSTIC DELAY BASED ON REGION OF ONSET

Diagnostic delay in bulbar-onset ALS

Diagnostic delay in ALS is irrefutably influenced by the site of symptom onset [7–10, 12]. There will be differences in terms of the diagnostic journey for those with bulbar onset, limb onset, or axial/respiratory onset. Alternative diagnoses will be considered, unique diagnostic studies will be ordered, and referrals to non-neurology subspecialists may ensue. All these factors may ultimately result in poor patient outcomes.

Patients with bulbar-onset disease, manifesting initially as dysarthria or dysphagia, tend to have a shorter diagnostic delay and are referred to a neurologist sooner than those with limb onset. The average delay to diagnosis in bulbar-onset ALS is 7–10 months, compared to 10–22 months for limb-onset disease, with a 2- to 12-month difference between the groups [7–10, 12, 19, 20, 23, 26, 28]. The theory behind this discrepancy is that those with more rapidly progressive ALS symptoms will seek care earlier, resulting in an earlier diagnosis, and that bulbar-onset ALS has a tendency to be a more rapidly progressive phenotype [29–31]. However, in a recent study including five European countries, bulbar onset and faster disease progression rate were two independent predictors of a shorter time to diagnosis in some centers [12].




FIGURE 1 Pathway to amyotrophic lateral sclerosis diagnosis from first symptom onset to final diagnosis. Initial delay to first evaluation (usually by a primary care provider) is 3–6 months on average [1,4-6,9,10,15-20,23-27]. Approximately 60% of patients are then referred to neurologists, while the remaining 40% are referred to non-neurologists. In some studies, referral to one or the other does not appear to affect diagnostic delay, especially when the neurologist is the first, second [4], or even the third consultant [20]. Reproduced with permission from Figure 1 in Richards et al [1].

Considering bulbar-onset ALS presents with dysarthria and dysphagia, these patients may be mistaken for having had a brainstem stroke [23, 32]. In contrast to the progressive nature of ALS, strokes are acute in onset. A brainstem tumor or demyelinating lesion could too be mistaken for bulbar-onset ALS, although these conditions are readily identifiable on contrasted magnetic resonance imaging. Myasthenia gravis associated with muscle-specific tyrosine kinase (MuSK) antibodies warrants particular consideration. MuSK myasthenia gravis can present with progressive dysarthria and dysphagia, and may be associated with tongue atrophy. Electrodiagnostic studies are essential to differentiate between MuSK myasthenia gravis and ALS, because PlwALS show neurogenic changes and fasciculation in the affected muscles, in general. Other conditions that mimic bulbar-onset ALS include syringobulbia and facial-onset sensory and motor neuronopathy; however, a large group of bulbar-onset patients are diagnosed initially with vocal cord dysfunction, dental problems, medication side effects, or anxiety/depression [1].

Due to the symptoms of dysarthria and dysphagia, it is common for patients with bulbar-onset ALS to be referred to subspecialists such as gastroenterologists, otolaryngologists, or stroke neurologists. Turner et al. found that 39% of PlwALS were referred to other specialists prior to a neurologist, and of these patients, 54% went to see an otolaryngologist first [23]. The delay to diagnosis, once seen by a physician, appears to be shorter for those referred first to a neurologist, rather than a non-neurologist (3 vs. 6 months in one series), whereas another study found no impact on diagnostic latency or overall survival [10, 12, 15, 23].

Delay to diagnosis and establishing care with a multidisciplinary clinic undeniably result in worse outcomes. Bulbar-onset patients are known to have poorer quality of life, increased risk of respiratory failure, sooner need for noninvasive ventilatory support and percutaneous gastrostomy tubes, and shorter survival rate [33]. Delayed access to multidisciplinary care may result in malnutrition

and weight loss—both poor prognostic indicators—considering these patients need regular assessment of swallow function and monitoring of weight [34–38]. Because bulbar-onset PlwALS are evaluated and referred for gastrostomy tube placement from the multidisciplinary clinic, delays to accessing this clinic and subsequently having the gastrostomy placed likely negatively impact survival and quality of life [38–41]. A recent study, however, called into question the survival benefit of gastrostomy tube placement in PlwALS [42].

Diagnostic delay in limb-onset ALS

Approximately 70% of PlwALS first present with symptoms from the extremities, that is, limb onset [43]. Typically, the initial symptoms are mild and nonspecific (e.g., unilateral foot drop or hand weakness), which makes recognizing the signs of serious neurological disease difficult for both patient and physician. For all PlwALS, the average time from first symptom to diagnosis is approximately 1 year [6, 9, 10, 18, 24, 44–46]. In patients with limb onset (particularly lower-limb onset), the delay is slightly longer compared to patients with bulbar onset [6–10, 12, 44, 46]. The diagnostic delay, which is substantial relative to the expected survival time in ALS, can be divided into patient's and doctor's delay. The median time for the former is reported to be approximately 3–4 months [6, 44, 45], slightly longer (5 months) specifically for lower-limb onset [44]. The delay in seeking medical care is probably related to the insidious and slow onset and the nonspecific nature of the symptoms. Doctor's delay, which comprises the rest of the total diagnostic delay, is likely also influenced by the slow and nonspecific presentation that may mimic a variety of other conditions, non-neurological and neurological [47]. In addition, most PlwALS first present to a general practitioner, who might not have extensive experience in neuromuscular disease. Consequently, many PlwALS are initially directed

to specialties other than neurology, such as physiotherapy, orthopedics, or spinal/hand surgery, and more than half receive an alternate diagnosis at some point during the investigation [6, 9, 10, 18, 24, 44, 45]. This proportion is slightly higher in limb-onset patients, in whom symptoms are frequently misinterpreted as the result of degenerative spinal disease or peripheral neuropathy. Importantly, a small group of patients undergo surgery (e.g., spinal surgery, in 3%–10%) for symptoms that are later attributed to ALS [9, 18, 24, 48, 49]. However, there is frequently coexistence of spinal degenerative disease in PlwALS, complicating diagnosis and treatment decisions [50]. A major problem hampering efforts to shorten the diagnostic delay is the lack of specific tests to identify the disease at an early stage. Thus, a prompt diagnosis often depends on the clinical skills and experience of the physician seeing the patient. For limb-onset patients, there are some relatively specific signs, such as fasciculations, lack of sensory symptoms, split-hand phenomenon, and the focal pattern of progression that may prompt the general practitioner to refer the patient to a neurologist [22, 47]. In one study, electromyography (EMG) was requested by 20% of the non-neurologists and by 75% of the neurologists as part of the diagnostic workup; in the latter group, EMG was essential in the diagnosis for the 45% of neurologists who established the diagnosis at the initial assessment [12].

Diagnostic delay in axial/respiratory onset

Respiratory onset is an unusual mode of presentation in PlwALS, representing 3% to 5% [51–55]. Development of respiratory impairment may be either acute or insidious [51, 53, 54, 56, 57]. Acute respiratory onset is so rarely reported in ALS that this frequently drives patients to tracheostomy (because of hypercapnic respiratory failure) before the diagnosis is established [53, 54, 56]. Insidious onset of respiratory disturbance also leads to diagnostic delay because respiratory symptoms are more frequently associated with lung or heart diseases [51, 53, 54, 56, 57]. Despite this, the diagnostic delay tends to be shorter for this subgroup, characterized by a phenotype of predominant lower motor neurone signs, middle-aged men, and marked weight loss [55].

There is an urgent need to ameliorate clinicians' awareness of these nonclassic presentations of ALS, because initiation of noninvasive ventilation could significantly prolong survival for 15 months (36.4 months, vs. 21.5 months if patients decline noninvasive ventilation; $p=0.02$) [53]. Although the positive impact of early noninvasive ventilation adaptation has been confirmed in a recent report, this finding should be confirmed in a future prospective study in a larger population of patients [55]. To shorten diagnostic delay in this group of patients, clinicians should consider ALS diagnosis in patients with idiopathic progressive respiratory failure, orthopnea, weight loss, atrophic limbs with fasciculations, or axial extension of the motor weakness causing weak neck muscles and head drop [53–55].

Nonetheless, head drop is commonly caused by isolated neck extensor myopathy—which represents more than 30% of the cases—but

also myasthenia gravis or some neuropathies such as chronic inflammatory demyelinating polyneuropathy, Parkinson's disease, or myositis. Only 7% of the cases are associated with ALS [58]. Whatever the cause, these patients experience increasing discomfort, distressing social interactions, and mobility impairment [59].

DISCUSSION/FUTURE DIRECTIONS

Diagnosis of ALS is still significantly delayed in most cases. There are similar diagnostic delays across distinct national healthcare systems, and there is no evidence of improvement in recent years [60]. The main problem is likely late referral to a neurologist by the first examining physician because most patients see a general practitioner initially [6]. A number of obstacles to early diagnosis include misdiagnoses, erroneous referrals to various specialists, and unnecessary investigations or surgeries. Unnecessary surgeries can hasten functional decline and markedly contribute to diagnostic delay [61]. These delays are particularly relevant in limb-onset patients, young-onset ALS, and slow progressors, due to a wider differential diagnoses range [60].

People with ALS are often misdiagnosed with a condition that mimics ALS, especially early in the disease course. Physicians must be attuned to the overlapping clinical presentations of myasthenia gravis, myopathic conditions (e.g., inclusion body myositis), and degenerative disc disease resulting in myelopathies and radiculopathies, as examples. Just as PlwALS are disadvantaged by misdiagnoses and unnecessary testing and treatment, those patients with an ALS mimic, who are misdiagnosed as having ALS, will have delayed access to potentially curative treatments, depending on the condition.

Even for experienced neurologists, the diagnosis of ALS can be challenging when a patient presents early in the disease course. EMG is often a decisive investigation, particularly when there is a paucity of clinical signs and symptoms. EMG evaluation has been shown to contribute to diagnosis in as many as 90% of ALS cases [12, 62]. The benefit of the new and simpler diagnostic criteria to shorten diagnostic time by neurologists is still unknown [62]. One reason that could hinder a faster diagnostic process by some neurologists is hesitation in giving patients a terminal diagnosis. Rapid-access ALS clinics and EMG facilities may have the greatest impact on diagnostic delays.

Timely diagnosis is key for more effective clinical management, will enable maximum benefit from disease-modifying therapies, and facilitates recruitment for clinical trials. Early referral to neuromuscular specialists and multidisciplinary clinics permits rapid pharmacological and supportive interventions, particularly rehabilitation, nutritional, and respiratory care. It has been shown that multidisciplinary ALS care has a positive impact on quality of life and survival [63]. Moreover, a study performed in Ireland showed that expedited referral to multidisciplinary clinics reduced costs significantly, a relevant point to emphasize [20]. Shorter time to diagnosis decreases the distress associated with multiple investigations and diagnostic

uncertainty; further, it permits earlier and unhurried life planning, specifically in the social, professional, economic, and familial dimensions, as well as affording time for some patients seeking spiritual support [5].

Sensitive, commercially available ALS blood biomarkers remain elusive. Therefore, educational programs should be promoted to facilitate a faster referral of suspected patients to neuromuscular specialists or multidisciplinary clinics—which has been tested with success in the past [16]. Indeed, quick referral to multidisciplinary clinics can shorten diagnostic time as much as 4 months [13]. A more sensitive issue is the utility and perils of educating the general public because it could create social anxiety without major benefit. More dedicated research is required to define the effective message to deliver to other medical specialists to triage the right cases appropriately, thus obviating an unnecessary surplus of referred patients. Developing a list of warning signs of possible ALS to disseminate to non-ALS providers should be a future goal.

The US-based ALS Association, in partnership with the Time to Diagnosis Working Group—which included ALS experts, patients, caregivers, and industry representatives—developed the thinkALS Tool, which was presented at the 32nd International Symposium on ALS/MND [64]. This tool serves as a diagnostic guide and was developed to be used by general neurologists to quickly determine if a patient has symptoms and signs suspicious for ALS. If a patient is suspected to have ALS, the neurologist could then quickly triage this patient to a multidisciplinary care clinic for additional diagnostic evaluation and management, thereby reducing the diagnostic delay. The thinkALS website and tool are free and in the public domain [65].

A similar tool, the MND Red Flag tool, was developed by the Royal College of General Practitioners and the Motor Neurone Disease Association [66]. This tool has been in use for a number of years. The weakness of such tools is that they require the physician or general practitioner to first consider if the constellation of symptoms and signs could be ALS before they consult the tools [22].

In many cases, we observed that patients, their family, and friends had already suspected that ALS was the most probable diagnosis or, in extreme cases, researched their symptoms and consulted the ALS specialist directly. When a physician has a persistent diagnostic uncertainty, this raises concerns for patients and family members, including lack of trust in providers and loss of faith in the diagnostic process. Therefore, a better diagnostic strategy to be shared with the medical community by ALS specialists is required.

AUTHOR CONTRIBUTIONS

Kelly G. Gwathmey: Supervision (lead); writing original draft (equal); writing, reviewing and editing (equal). **Philippe Corcia:** Writing original draft (equal); writing, reviewing and editing (equal). **Chris J. McDermott:** Writing original draft (equal); writing, reviewing and editing (equal). **Angela Genge:** writing, reviewing and editing (equal). **Stefan Sennfalt:** Writing original draft (equal); writing, reviewing and editing (equal). **Mamede de Carvalho:** Writing original draft (equal); writing, reviewing and editing (equal). **Caroline Ingre:** Supervision

(lead); writing original draft (equal); writing, reviewing and editing (equal).

ACKNOWLEDGMENTS

Dr McDermott is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre Sheffield and an NIHR Research Professorship. Open access funding was enabled and organized by Cytokinetics. Editorial and creative support was provided by iLuma Medical Communications.

CONFLICT OF INTEREST STATEMENT

Kelly G. Gwathmey: consulting for Alexion, Argenx, Cytokinetics and UCB; speaker for Alexion. Philippe Corcia: consulting for Amylyx Pharmaceuticals, Biogen and Cytokinetics; grant/research support from Biogen. Chris J. McDermott: consulting for Amylyx, Biogen, Cytokinetics and PTC Therapeutics (paid to employer). Angela Genge: clinical trial consulting for AL-S Pharma, Eli Lilly and Qoralis; regulatory consulting for Amylyx and Biogen; speaker for Amylyx, MTPA and Qoralis; consulting for Cytokinetics. Stefan Sennfalt: none. Mamede de Carvalho: grant/research support from Biogen, Cytokinetics and Pfizer; consulting for Biogen, Cytokinetics, GlaxoSmithKline and Kedrion Biopharma. Caroline Ingre: consulting and speaker for Cytokinetics.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Kelly G. Gwathmey  <https://orcid.org/0000-0002-7589-8826>
Philippe Corcia  <https://orcid.org/0000-0002-1625-8845>
Chris J. McDermott  <https://orcid.org/0000-0002-1269-9053>
Angela Genge  <https://orcid.org/0000-0001-5587-9946>
Stefan Sennfalt  <https://orcid.org/0000-0002-7114-2757>
Mamede de Carvalho  <https://orcid.org/0000-0001-7556-0158>
Caroline Ingre  <https://orcid.org/0000-0001-5327-7204>

REFERENCES

- Richards D, Morren JA, Piro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. *J Neurol Sci.* 2020;417:117054. doi:10.1016/j.jns.2020.117054
- Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. *Brain J Neurol.* 2012;135(pt 3):847-852. doi:10.1093/brain/awr351
- Ackrivo J, Hansen-Flaschen J, Wileyto EP, Schwab RJ, Elman L, Kawut SM. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. *Eur Respir J.* 2019;53(4):1802237. doi:10.1183/13993003.02237-2018
- Chiò A. ISIS survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. *J Neurol.* 1999;246(suppl 3):III1-III5, III5. doi:10.1007/BF03161081
- Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? *J Neurol Sci.* 2000;180(1-2):76-81. doi:10.1016/s0022-510x(00)00418-4
- Paganoni S, Macklin EA, Lee A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). *Amyotroph*

- Lateral Scler Frontotemporal Degener.* 2014;15(5–6):453–456. doi:10.3109/21678421.2014.903974
7. Khishchenko N, Allen KD, Coffman CJ, et al. Time to diagnosis in the National Registry of veterans with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2010;11(1–2):125–132. doi:10.3109/17482960802572681
8. Zoccollella S, Beghi E, Palagano G, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. *J Neurol Sci.* 2006;250(1–2):45–49. doi:10.1016/j.jns.2006.06.027
9. Kraemer M, Buerger M, Berlit P. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. *Clin Neurol Neurosurg.* 2010;112(2):103–105. doi:10.1016/j.clineuro.2009.10.014
10. Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: the problem continues. *J Neurol Sci.* 2014;343(1–2):173–175. doi:10.1016/j.jns.2014.06.003
11. Donaghy C, Dick A, Hardiman O, Patterson V. Timeliness of diagnosis in motor neurone disease: a population-based study. *Ulster Med J.* 2008;77(1):18–21.
12. Falcão de Campos C, Gromicho M, Uysal H, et al. Delayed diagnosis and diagnostic pathway of ALS patients in Portugal: where can we improve? *Front Neurol.* 2021;12:761355. doi:10.3389/fneur.2021.761355
13. Martínez-Molina M, Argente-Escrig H, Polo MF, et al. Early referral to an ALS center reduces several months the diagnostic delay: a multicenter-based study. *Front Neurol.* 2020;11:604922. doi:10.3389/fneur.2020.604922
14. Calvo A, Moglia C, Lunetta C, et al. Factors predicting survival in ALS: a multicenter Italian study. *J Neurol.* 2017;264(1):54–63. doi:10.1007/s00415-016-8313-y
15. Palese F, Sartori A, Logrosino G, Pisa FE. Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. *Amyotroph Lateral Scler Frontotemporal Degener.* 2019;20(3–4):176–185. doi:10.1080/21678421.2018.1550517
16. Mitchell JD, Callaghan P, Gardham J, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)—a 20-year review: can we do better? *Amyotroph Lateral Scler.* 2010;11(6):537–541. doi:10.3109/17482968.2010.495158
17. Armstrong MD, Hansen G, Schellenberg KL. Rural residence and diagnostic delay for amyotrophic lateral sclerosis in Saskatchewan. *Can J Neurol Sci.* 2020;47(4):538–542. doi:10.1017/cjn.2020.38
18. Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. *J Neurol Sci.* 1996;139(suppl):110–116. doi:10.1016/0022-510x(96)00088-3
19. Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. *Clin Neurol Neurosurg.* 2012;114(6):550–554. doi:10.1016/j.clineuro.2011.11.026
20. Galvin M, Ryan P, Maguire S, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population-based study of consultations, interventions and costs. *PLoS One.* 2017;12(6):e0179796. doi:10.1371/journal.pone.0179796
21. Sirri L, Fava GA, Sonino N. The unifying concept of illness behavior. *Psychother Psychosom.* 2013;82(2):74–81. doi:10.1159/000343508
22. Baxter S, McDermott CJ. Decision-making and referral processes for patients with motor neurone disease: a qualitative study of GP experiences and evaluation of a new decision-support tool. *BMC Health Serv Res.* 2017;17(1):339. doi:10.1186/s12913-017-2286-0
23. Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. *J Neurol Sci.* 2010;294(1–2):81–85. doi:10.1016/j.jns.2010.03.028
24. Belsh JM, Schiffman PL. Misdiagnosis in patients with amyotrophic lateral sclerosis. *Arch Intern Med.* 1990;150(11):2301–2305.
25. Vázquez-Costa JF, Martínez-Molina M, Fernández-Polo M, Fornés-Ferrer V, Frascuet-Carrera M, Sevilla-Mantecón T. Análisis del trayecto y retraso diagnóstico de los pacientes con esclerosis lateral amiotrófica en la Comunidad Valenciana. *Neurología.* 2021;36(7):504–513. doi:10.1016/j.nrl.2018.03.026
26. Kano O, Iwamoto K, Ito H, et al. Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset. *BMC Neurol.* 2013;13:19. doi:10.1186/1471-2377-13-19
27. Rocchetti I, Taruscio D, Pierannunzio D. Modeling delay to diagnosis for amyotrophic lateral sclerosis: under reporting and incidence estimates. *BMC Neurol.* 2012;12(1):160. doi:10.1186/1471-2377-12-160
28. Zoccollella S, Beghi E, Palagano G, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. *J Neurol Sci.* 2008;268(1–2):28–32. doi:10.1016/j.jns.2007.10.023
29. Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. *Lancet Neurol.* 2018;17(5):423–433. doi:10.1016/S1474-4422(18)30089-9
30. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. *Brain.* 1995;118(pt 3):707–719. doi:10.1093/brain/118.3.707
31. Christensen PB, Højer-Pedersen E, Jensen MDNB. Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. *Neurology.* 1990;40(4):600–604. doi:10.1212/WNL.40.4.600
32. Belsh JM. Diagnostic challenges in ALS. *Neurology.* 1999;53(8 suppl 5):S26–S30. discussion S35–S36.
33. Young CA, Ealing J, McDermott C, et al. The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. *Amyotroph Lateral Scler Frontotemporal Degener.* 2019;20(5–6):317–327. doi:10.1080/21678421.2019.1615951
34. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. *Neurology.* 1999;53(5):1059. doi:10.1212/WNL.53.5.1059
35. Jawaid A, Murthy SB, Wilson AM, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. *Amyotroph Lateral Scler.* 2010;11(6):542–548. doi:10.3109/17482968.2010.482592
36. Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. *J Neurol Neurosurg Psychiatry.* 2011;82(6):628–634. doi:10.1136/jnnp.2010.211474
37. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis: body mass index predicts survival in ALS. *Muscle Nerve.* 2011;44(1):20–24. doi:10.1002/mus.22114
38. The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. *Eur J Neurol.* 2012;19(3):360–375. doi:10.1111/j.1468-1331.2011.03501.x
39. Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. *J Neurol Sci.* 2011;304(1–2):44–48. doi:10.1016/j.jns.2011.02.016
40. Fasano A, Fini N, Ferraro D, et al. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. *Amyotroph Lateral Scler Frontotemporal Degener.* 2017;18(3–4):233–242. doi:10.1080/21678421.2016.1270325
41. Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. *PLoS One.* 2017;12(5):e0177555. doi:10.1371/journal.pone.0177555

42. Vergonjeanne M, Fayemendy P, Marin B, et al. Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. *Clin Nutr*. 2020;39(10):3112-3118. doi:10.1016/j.clnu.2020.01.018
43. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. *Lancet*. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7
44. Sennfält S, Kläppe U, Thams S, et al. The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression. *Amyotroph Lateral Scler Frontotemporal Degener*. 2023;24(1-2):45-53. doi:10.1080/21678421.2022.2053722
45. Galvin M, Madden C, Maguire S, et al. Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study. *BMC Health Serv Res*. 2015;15:571. doi:10.1186/s12913-015-1229-x
46. Matharan M, Mathis S, Bonabaud S, Carla L, Soulages A, Le Masson G. Minimizing the diagnostic delay in amyotrophic lateral sclerosis: the role of nonneurologist practitioners. *Neurol Res Int*. 2020;2020:1473981. doi:10.1155/2020/1473981
47. Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. *Pract Neurol*. 2013;13(3):153-164. doi:10.1136/practneurol-2013-000557
48. Yoshor D, Klugh A, Appel SH, Haverkamp LJ. Incidence and characteristics of spinal decompression surgery after the onset of symptoms of amyotrophic lateral sclerosis. *Neurosurgery*. 2005;57(5):984-989; discussion 984-989. doi:10.1227/01.neu.0000180028.64385.d3
49. Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA. Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. *Muscle Nerve*. 2006;34(3):359-360. doi:10.1002/mus.20555
50. Yamada M, Furukawa Y, Hirohata M. Amyotrophic lateral sclerosis: frequent complications by cervical spondylosis. *J Orthop Sci*. 2003;8(6):878-881. doi:10.1007/s00776-003-0712-0
51. Nightingale S, Bates D, Bateman DE, Hodgson P, Ellis DA, Gibson GJ. Enigmatic dyspnoea: an unusual presentation of motor-neurone disease. *Lancet*. 1982;1(8278):933-935. doi:10.1016/s0140-6736(82)91934-1
52. Al-Shaikh B, Kinnear W, Higenbottam TW, Smith HS, Shneerson JM, Wilkinson I. Motor neurone disease presenting as respiratory failure. *Br Med J (Clin Res Ed)*. 1986;292(6531):1325-1326. doi:10.1136/bmj.292.6531.1325
53. Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. *J Neurol Neurosurg Psychiatry*. 2007;78(6):629-631. doi:10.1136/jnnp.2006.103564
54. Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. *Amyotroph Lateral Scler*. 2010;11(4):379-382. doi:10.3109/17482960903426543
55. Pinto S, Gromicho M, Oliveira Santos MO, Swash M, De Carvalho M. Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern. *Amyotroph Lateral Scler Frontotemporal Degener*. 2022;5:1-5. doi:10.1080/21678421.2022.2067777
56. Kuisma MJ, Saarinen KV, Teirmaa HT. Undiagnosed amyotrophic lateral sclerosis and respiratory failure. *Acta Anaesthesiol Scand*. 1993;37(6):628-630. doi:10.1111/j.1399-6576.1993.tb03778.x
57. de Carvalho M, Matias T, Coelho F, Evangelista T, Pinto A, Luís ML. Motor neuron disease presenting with respiratory failure. *J Neurol Sci*. 1996;139(suppl):117-122. doi:10.1016/0022-510x(96)00089-5
58. Drain JP, Virk SS, Jain N, Yu E. Dropped head syndrome: a systematic review. *Clin Spine Surg*. 2019;32(10):423-429. doi:10.1097/BSD.0000000000000811
59. Wacławik AJ, Lotz BP, Beinlich BR, Brooks BR. Dropped head syndrome. *Neurology*. 1997;48(2):550-551; author reply 551-552. doi:10.1212/wnl.48.2.550-b
60. Falcão de Campos C, Gromicho M, Uysal H, et al. Trends in the diagnostic delay and pathway for amyotrophic lateral sclerosis patients across different countries. *Front Neurol*. 2023;13:1064619. doi:10.3389/fneur.2022.1064619
61. Pinto S, Swash M, de Carvalho M. Does surgery accelerate progression of amyotrophic lateral sclerosis? *J Neurol Neurosurg Psychiatry*. 2014;85(6):643-646. doi:10.1136/jnnp-2013-305770
62. Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. *Clin Neurophysiol*. 2020;131(8):1975-1978. doi:10.1016/j.clinph.2020.04.005
63. Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G, PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. *J Neurol Neurosurg Psychiatry*. 2006;77(8):948-950. doi:10.1136/jnnp.2005.083402
64. Yersak J, Birhane S, Heiman-Patterson T, Lomen-Hoerth C, Oskarrson B, Babu S. CMS-03 ThinkALS: a user-friendly and comprehensive ALS diagnosis and referral tool for general neurologists. *Amyotroph Lateral Scler Front Degener*. 2021;22(suppl 2):202-233. doi:10.1080/21678421.2021.1985802
65. ThinkALS. The ALS Association. Accessed January 27, 2023. <https://www.als.org/thinkals>.
66. Red Flag Diagnosis Tool. MND Association. Accessed January 27, 2023. <https://www.mndassociation.org/professionals/management-of-mnd/management-by-specific-professions/information-for-gps/red-flag-diagnosis-tool/>. Published November 2, 2022.

How to cite this article: Gwathmey KG, Corcia P, McDermott CJ, et al. Diagnostic delay in amyotrophic lateral sclerosis. *Eur J Neurol*. 2023;00:1-7. doi:10.1111/ene.15874